Tracy L. Bahl: The Importance of Adopting Anticancer Biosimilars

Tracy L. Bahl, president and chief executive officer of OneOncology, discusses why his organization felt it was key to adopt biosimilars.


Well, it's fundamental to what OneOncology hopes we can bring to the clinical care marketplace. The biosimilar advances have allowed us to not only continue to bring great clinical care, but to lower the cost thereof. Financial toxicity is one of the greatest barriers to effective treatment in the cancer continuum, and biosimilars provide comparable, and sometimes even better, clinical care for a significantly lower cost. And that allows us to reduce costs over the long term and certainly can help to reduce out-of-pocket costs for our patients.